Can bringing addiction treatment to syringe programs save more lives?

NCT ID NCT07631598

Not yet recruiting Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay on medication for opioid use disorder compared to referring them elsewhere. About 512 adults who use SSPs and have moderate to severe opioid use disorder will take part. The goal is to see if on-site, easy-access treatment improves retention and reduces overdoses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER, MODERATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID USE DISORDER, MODERATE OPIOID USE DISORDER, SEVERE OPIOID-USE DISORDER

Contacts and locations

Show contact details

Locations

Alianza of New Mexico

Roswell, New Mexico, 88203, United States
CARPBR/Be Safe Syringe Program

Baton Rouge, Louisiana, 70806, United States
Challenges, Inc/Prisma Health

Greenville, South Carolina, 29605, United States
Community Health Project Los Angeles (CHPLA)

Los Angeles, California, 90029, United States

Contact Email: •••••@•••••
HIPS

Washington D.C., District of Columbia, 20002, United States
HIV Alliance

Grants Pass, Oregon, 97526, United States
Harm Reduction Sisters

Duluth, Minnesota, 55805, United States
Vivent Health

Milwaukee, Wisconsin, 53212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.